| Literature DB >> 22903236 |
Minoru Tada1, Akiko Ishii-Watabe, Keiko Maekawa, Hiromi Fukushima-Uesaka, Kouichi Kurose, Takuo Suzuki, Nahoko Kaniwa, Jun-Ichi Sawada, Nana Kawasaki, Takako Eguchi Nakajima, Ken Kato, Yasuhide Yamada, Yasuhiro Shimada, Teruhiko Yoshida, Takashi Ura, Miyuki Saito, Kei Muro, Toshihiko Doi, Nozomu Fuse, Takayuki Yoshino, Atsushi Ohtsu, Nagahiro Saijo, Haruhiro Okuda, Tetsuya Hamaguchi, Yoshiro Saito, Yasuhiro Matsumura.
Abstract
Fcγ receptor IIa (FcγRIIa) plays an important role in antibody-dependent cellular cytotoxicity and inflammation. Changes in FcγRIIa expression levels or activity caused by genetic polymorphisms in FCGR2A, the gene encoding FcγRIIa, may lead to differences in disease progression as well as efficacy of antibody therapeutics between individuals. In this study, we sequenced the 5'-flanking region along with all exons and their flanking regions of FCGR2A from 111 Japanese subjects. Forty-eight genetic variations were found including 12 novel ones. Beside the well-known functional 497A > G (H166R) polymorphism, we detected 818T > C (L273P) at 0.005 frequency. Since the functional significance of this polymorphism has not been revealed, we next assessed the functions of the L273P substitution by expressing wild-type and the variant proteins in human Jurkat cells. The L273P variant protein showed similar cell surface expression and IgG-binding properties as the wild-type, but it exhibited a stronger signal transduction activity based on the approximately 2-fold enhancement of tyrosine phosphorylation of FcγRIIa itself. The current results suggest that L273P could have functional significance in the antibody-dependent clinical responses through FcγRIIa.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22903236 DOI: 10.1007/s00251-012-0646-9
Source DB: PubMed Journal: Immunogenetics ISSN: 0093-7711 Impact factor: 2.846